About Vasopressin V1b receptor
Vasopressin V1b receptor (AVPR1B) is a protein
from Homo sapiens identified by UniProt accession
P47901, 424 residues long.
MolForge cross-references it against 0 known binders and
147 disease associations.
Target properties
| Protein name | Vasopressin V1b receptor |
| UniProt accession | P47901 |
| Gene | AVPR1B |
| Organism | Homo sapiens |
| Length | 424 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (147)
Diseases linked to this target (Open Targets).
- hemorrhage · score 0.59
- enuresis · score 0.59
- diabetes insipidus · score 0.58
- Nasal congestion · score 0.56
- septic shock · score 0.56
- Abdominal distention · score 0.55
- Central diabetes insipidus · score 0.55
- hepatorenal syndrome · score 0.53
- head injury · score 0.53
- hemophilia A · score 0.53
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P47901-F1 | alphafold | PREDICTED | 73.67 | — |
Amino-acid sequence (424 residues)
MDSGPLWDAN PTPRGTLSAP NATTPWLGRD EELAKVEIGV LATVLVLATG GNLAVLLTLG QLGRKRSRMH LFVLHLALTD LAVALFQVLP QLLWDITYRF QGPDLLCRAV KYLQVLSMFA STYMLLAMTL DRYLAVCHPL RSLQQPGQST YLLIAAPWLL AAIFSLPQVF IFSLREVIQG SGVLDCWADF GFPWGPRAYL TWTTLAIFVL PVTMLTACYS LICHEICKNL KVKTQAWRVG GGGWRTWDRP SPSTLAATTR GLPSRVSSIN TISRAKIRTV KMTFVIVLAY IACWAPFFSV QMWSVWDKNA PDEDSTNVAF TISMLLGNLN SCCNPWIYMG FNSHLLPRPL RHLACCGGPQ PRMRRRLSDG SLSSRHTTLL TRSSCPATLS LSLSLTLSGR PRPEESPRDL ELADGEGTAE TIIF
Explore Vasopressin V1b receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets